When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Fluticasone furoate/umeclidinium bromide/vilanterol - Wikipedia

   en.wikipedia.org/wiki/Fluticasone_furoate/...

   The combination fluticasone furoate/umeclidinium bromide/vilanterol product is approved by the US Food and Drug Administration with an indication for the maintenance treatment of a chronic lung problem called chronic obstructive pulmonary disease (COPD) in adults who (1) have already tried fluticasone furoate/vilanterol (brand name Breo Ellipta) but are still experiencing symptoms of airway ...

3. Fluticasone furoate - Wikipedia

   en.wikipedia.org/wiki/Fluticasone_furoate

   The combination drugs fluticasone furoate/umeclidinium bromide/vilanterol, marketed as Trelegy Ellipta, and fluticasone furoate/vilanterol, marketed as Breo Ellipta (US, Canada, New Zealand) and Relvar Ellipta (EU, UK), [33] [34] [35] are approved for use in the United States for long-term maintenance treatment of airflow obstruction in people ...

4. Umeclidinium bromide - Wikipedia

   en.wikipedia.org/wiki/Umeclidinium_bromide

   Umeclidinium bromide, sold under the brand name Incruse Ellipta, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). [3] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol ) [ 4 ] [ 5 ] and also as a triple-therapy ...

5. Glaxo/Innoviva File for Approval of Trelegy Ellipta in Japan

   www.aol.com/news/glaxo-innoviva-file-approval...

   Main Menu. News

6. Glaxo/Innoviva's Trelegy Ellipta Gets FDA Nod for Asthma - AOL

   www.aol.com/news/glaxo-innovivas-trelegy-ellipta...

   With the approval for the asthma indication, Glaxo's (GSK) Trelegy becomes the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD.

7. GSK's Trelegy Ellipta meets key goal in late-stage ... - AOL

   www.aol.com/news/gsks-trelegy-ellipta-meets-key...

   British drugmaker GlaxoSmithKline Plc said on Thursday that its respiratory drug Trelegy Ellipta met the main goal of a late-stage asthma study, signalling a possible boost to its lung medicines ...